ADPKD is the leading, inheritable cause of kidney failure in the US, occurring in approximately 116,000 patients1
ADPKD is a genetic form of CKD caused by mutations in the PKD1 and PKD2 genes1-3
Genetic mutations cause the formation of fluid-filled cysts in the kidneys1-3
Cyst growth displaces normal kidney tissue, triggers an immune response leading to interstitial inflammation and fibrosis, and results in progressive loss of kidney function and eventual kidney failure1-3
PHOENIX Trial Overview
PHOENIX is an open-label, multicenter, phase 2 US trial designed to evaluate the safety, tolerability, and efficacy of bardoxolone methyl in four separate patient cohorts. The target enrollment is 25 to 30 patients per cohort.
PHOENIX Trial Details
Patient cohorts: ADPKD, IgAN, T1D CKD, and FSGS
Age: 18-65 years
eGFR: 30-90 mL/min/1.73 m2
Primary endpoint: change from baseline in eGFR at week 12
Treatment: bardoxolone methyl, orally, once-daily for 12 weeks
National Human Genome Research Institute. Learning about autosomal dominant polycystic kidney disease. http://www.genome.gov/20019622/learning-about-autosomal-polycystic-kidney-disease. Accessed November 7, 2018.
Li X, Magenheimer BS, Xia S, et al. A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease. Nat Med. 2008;14(8):863-868.